Directorate Change
Juliet Thompson appointed as Independent Non-Executive Director and Audit Committee Chair from 30 June 2025.
Select text to share a quote on X · sign in to keep highlights & notes in your AMS notes
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, is pleased to announce that our search for an additional Independent Non-Executive Director has successfully concluded and that Juliet Thompson will be appointed as a Non-Executive Director and Chair of the Audit Committee following the conclusion of the AGM on 30 June.
Juliet has over 30 years of finance, banking and board experience with significant focus in the healthcare sector. She is a proven FTSE 250 Audit Committee Chair and a former investment banker who has spent her career advising pharmaceutical and medtech companies. She played a leading role in setting up Code Securities, which was later acquired by Nomura (becoming Nomura Code) but remained independent. At Nomura Code, Juliet advised companies in the healthcare and clean tech sectors on their financing and strategic options. She worked on over 50 transactions including IPOs, secondary offerings, private placements and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences team where she advised CEOs and CFOs in the healthcare sector. She was Audit Committee Chair at Vectura Group Limited.
Juliet has built a diverse portfolio; she is currently a Non-Executive Director and Chair of the Audit Committees of: Indivior plc, a NASDAQ listed company working to develop medicines to treat addiction; Novacyt S.A., a Euronext and AIM listed diagnostic company; and Organox Limited, a private company spun out of Oxford University developing innovative solutions for organ preservation prior to transplantation. Juliet holds a BSc in Economics from the University of Bristol and qualified as a Chartered Accountant and holds an ACA from the Association of Chartered Certified Accountants.
Grahame Cook, Chair of AMS, said: "I am very pleased to welcome Juliet to the Board of AMS. She has a wealth of Board experience, particularly focused on healthcare companies, and is a proven Audit Committee Chair. She will be a valuable addition to our Board."
Juliet Thompson commented: "I have followed AMS progress over the last few years and am excited to be joining the Board as the company continues its growth journey."
Juliet will immediately be appointed as Chair of the Audit Committee and join the Nomination and Remuneration Committees. The composition of each of the Board Committees from 30 June 2025 is therefore confirmed as follows:
| Board Committee | Membership |
| Audit Committee | Juliet Thompson (Chair) Grahame Cook Douglas Le Fort Susan Searle |
| Nomination Committee | Grahame Cook (Chair) Douglas Le Fort Susan Searle Juliet Thompson |
| Remuneration Committee | Douglas Le Fort (Chair) Grahame Cook Susan Searle Juliet Thompson |
Juliet Thompson (aged 59 years) holds or has held Directorships and partnerships in the five years preceding her appointment at AMS as follows:
| Current Directorships | Previous Directorships |
| Indivior plc | Angle plc |
| OrganOx Ltd | Leadership Through Sport and Business |
| Novacyt Group | Opus 107 Limited |
| Opus Trust Investments Limited | Vectura Group Limited |
GI Dynamics, Inc
No further information in connection with her appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
| ICR Healthcare | Tel: +44 (0) 20 3709 5700 |
| Mary-Jane Elliott / Lucy Featherstone | AMS@icrhealthcare.com |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Gary Clarence / David Anderson | |
| Berenberg (Joint Broker) | Tel: +44 (0)20 3207 7800 |
Toby Flaux / Detlir Elezi / Yasmina Benchekroun
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.